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eply
e thank Dr. Raphael and colleagues for their interest in our
eport (1). The investigators report their own findings, which
emonstrate that patients with implantable cardioverter-
efibrillators have relatively poor understanding of their device as
t relates to options for deactivation. Their findings confirm our
revious qualitative work with patients as well (2). The investiga-
ors point out that if physicians think patients understand options
or deactivation, but in reality they do not, then this can be a reason
hat discussions about deactivation occur so rarely. We are in
omplete agreement with these investigators and did mention in
ur original contribution that this apparent incongruity between
hysician perception of patients’ knowledge and what patients’
ctually understand poses a challenge to communication about
eactivation. We thank Dr. Raphael and colleagues for highlight-
ng this important issue in their letter.
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ncidental Findings on
ardiac Computed Tomography
acHaalany et al. (1) recently reported that incidental findings
IFs) on computed tomography performed to diagnose coronary
rtery disease (CAD) are common but do not predict noncardiac
eath, and investigating them further “is not without cost or risk.”
Although we appreciate the detailed analysis of IFs and costs,
e believe a significant flaw affects the study design. Drawing
onclusions on whether mortality differs between patients with and
ithout IFs becomes statistically unsound if some patients receive
otentially lifesaving (or at least life-prolonging) interventions,
uch as lobectomy for lung carcinoma or chemotherapy for
ediastinal lymphoma. In other words, although Kaplan-Meier
urvival curves show no difference in survival between patients with
Fs and those without, any intervention that may prolong survival
eyond the reported follow-up time significantly impairs the
alidity of the analysis.
Moreover, the investigators recognize that an 18-month
ollow-up time may be inadequate to correctly evaluate indetermi-
ate IFs, as some of them may become significant with a longer
ollow-up time. We concur, but we also add that an 18-month
ollow-up time is probably inadequate even for the prognostic
valuation of the smaller number of IFs that were already signif-
cant, as they include disorders with a natural course that may be
onger than 18 months (2).
Further studies are certainly necessary to clarify whether any
enefit lies in further investigating indeterminate findings, but
rom the point of view of evidence-based medicine, that question
annot be answered by comparing a group of patients with IFs and
nother group without. A more appropriate study design would
xclude patients who already have a clear management pathway set
efore them (i.e., those without any IFs and those with an
mmediately significant IF) and randomize the remaining patients
ith indeterminate IFs to either further investigations or simple
ollow-up.
As the number of procedures increases, invasive cardiologists
ncreasingly will be called to acquire sufficient preparation to
onsider the global significance of imaging findings, and we
ppreciate the relevance of the work of MacHaalany et al. (1) in
hat direction.
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eply
e thank Drs. Bartoletti and colleagues for their interest in our
tudy (1).
If one could operate in a world without risk and that is
nconstrained by costs, all incidental findings (IFs) could be
nvestigated. However, the investigation of IFs must be tempered
y the reality that benefits may be offset by risks and costs. In this
nblinded observational study, mortality was chosen as the primary
utcome measure because it is least influenced by subjectivity.
lthough we agree that when interventions prevent or delay death
he mortality in 2 groups will likely favor equivalence, it is also
mportant to recognize that survival benefits may also be attributed
o lead-time bias.
We also agree that a longer follow-up duration may have better
acilitated appreciation of differences in outcomes between com-
arison groups, and this limitation has been acknowledged. How-
ver, none of the indeterminate IFs became clinically significant.
he majority of the patients were followed up until a diagnosis was
ade or until no further follow-up was recommended (i.e., the IF
as deemed benign). Even if inferior outcomes were noted in IF
atients, further studies would be needed to explain whether the
ssociation is causal or serendipitous, given the benign disposition
f IFs.Most important is the readers’ observation that more studies are
eeded and that a randomized controlled trial of patients with
ndeterminate IF would be ideal and should be encouraged.
owever, one must accept that randomizing patients with IFs
ould be seen as unethical and may not be clinically feasible at
any centers. Thus, it is important that results such as ours be
sed to encourage discussion and to cast doubt on our current
linical practice, thus opening the opportunity for researchers to
ustify such randomized controlled trials.
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